Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct:41 Suppl 1:19-45.
doi: 10.1002/hed.25932.

Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy

Jason Chia-Hsun Hsieh  1 , Hung-Ming Wang  1 , Min-Hsien Wu  1   2   3 , Kai-Ping Chang  4 , Pei-Hung Chang  5   6 , Chun-Ta Liao  4 , Chi-Ting Liau  1
Affiliations
Review

Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy

Jason Chia-Hsun Hsieh et al. Head Neck. 2019 Oct.

Abstract

Background: Biomarkers in head and neck squamous cell carcinoma (HNSCC) emerge rapidly in recent years, especially for new targeted therapies and immunotherapies.

Methods: Recent, relevant peer-reviewed evidence were critically reviewed and summarized.

Results: This review article briefly introduces essential biomarker concepts, including purposes and classifications (predictive, prognostic, and diagnostic markers), and the phases of biomarker development. We summarize current biomarkers in order of clinical utility; p16 and human papillomavirus status remain the most important and validated biomarkers in HNSCC. The rationale for biomarker study design continues to evolve with technological advances, especially whole-exome or whole-genomic sequencing. Noninvasive body fluid and liquid biopsy biomarkers appear to hold strong potential for development as tools for early cancer detection, cancer diagnosis, monitoring of disease recurrence, and outcome prediction. In light of discrepancies among different technologies, standardized approaches are needed.

Conclusion: Biomarkers from cancer tissue or blood in HNSCC could direct new anticancer therapies.

Keywords: biomarker; cisplatin; head and neck cancer; immunotherapy; liquid biopsy; targeted therapy.

PubMed Disclaimer

References

REFERENCES

    1. Definition of Biomarker - Nci Dictionary of Cancer Terms, https://www.cancer.gov/publications/dictionaries/cancer-terms/def/biomarker. (n.d.).
    1. Sawyers CL. The cancer biomarker problem. Nature. 2008;452(7187):548-552.
    1. Kang H, Kiess A, Chung CH. Emerging biomarkers in head and neck cancer in the era of genomics. Nat Rev Clin Oncol. 2015;12(1):11-26.
    1. Parkinson DR, McCormack RT, Keating SM, et al. Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer. Clin Cancer Res. 2014;20(6):1428-1444.
    1. Sawyers CL, Van't veer LJ. Reliable and effective diagnostics are keys to accelerating personalized cancer medicine and transforming cancer care: a policy statement from the American Association for Cancer Research. Clin Cancer Res. 2014;20(19):4978-4981.

Publication types

MeSH terms

Substances

LinkOut - more resources